Momenta Pharmaceuticals (MNTA) Announces Results From a Phase 1 Study of M118 Administered as a Subcutaneous Injection
More News related to MNTA
- Momenta Pharmaceuticals to Present At Upcoming Conferences
- Momenta Pharmaceuticals (MNTA) Tops Q3 View By A Penny
- Momenta Pharmaceuticals Reports Financial Results for the Third Quarter of 2008
- Momenta Pharmaceuticals to Present At Oppenheimer 19th Annual Healthcare Conference
- Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Third Quarter 2008 Financial Results
More News related to Corporate News
- B. Riley Downgrades Doral Financial (DRL) to Neutral
- CL King Downgrades Ceragon (CRNT) to Accumulate
- Matrix Upgrades/Downgrades for December 1, 2008
- Raymond James Downgrades Allscripts (MDRX) to Market Perform
- RBC Capital Downgrades Strategic Hotels & Resorts (BEE) to Underperform
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will present safety and tolerability results from a Phase I study of M118, its rationally engineered anticoagulant, in a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics Meeting. The poster, titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of M118, a Novel Rationally Engineered Low Molecular Weight Heparin Given as a Subcutaneous Injection in a Rising Dose Cohort Regimen in Healthy Subjects," reported that M118 was well-tolerated when administered to 36 subjects as a single-dose subcutaneous injection of up to 150 IU/kg (the highest dose evaluated). M118 is being developed as adjunctive pharmacotherapy to treat patients diagnosed with Acute Coronary Syndromes (ACS).
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.99Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
